b1: trop2 adc
Triple-negative Breast Cancer
Fudan Universityantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
447 Active assets in the Triple-negative Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capivasertib AstraZeneca | Phase 3 | BB |
Cyclophosphamide M.D. Anderson Cancer Center | Phase 4 | BB |
Carboplatin M.D. Anderson Cancer Center | Phase 4 | BB |
Veliparib National Cancer Institute (NCI) | Phase 3 | BB |
Atezolizumab European Institute of Oncology | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →